B. Riley Lowers Earnings Estimates for Bicycle Therapeutics

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Stock analysts at B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a research report issued to clients and investors on Monday, March 3rd. B. Riley analyst K. Patel now expects that the company will post earnings of ($3.75) per share for the year, down from their previous forecast of ($3.70). B. Riley has a "Neutral" rating and a $17.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share. B. Riley also issued estimates for Bicycle Therapeutics' Q4 2025 earnings at ($1.01) EPS, FY2026 earnings at ($4.34) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($3.92) EPS.

A number of other equities analysts have also recently weighed in on the company. JMP Securities decreased their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a report on Wednesday, December 18th. Needham & Company LLC restated a "buy" rating and set a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Stephens restated an "equal weight" rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.14.

Remove Ads

Bicycle Therapeutics Stock Performance

Shares of NASDAQ:BCYC traded down $0.42 during trading on Wednesday, reaching $10.23. 243,763 shares of the stock were exchanged, compared to its average volume of 298,858. The firm's 50-day moving average price is $12.77 and its 200 day moving average price is $18.89. The firm has a market cap of $706.34 million, a price-to-earnings ratio of -3.11 and a beta of 1.12. Bicycle Therapeutics has a 12-month low of $9.99 and a 12-month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $3.70 million during the quarter, compared to analysts' expectations of $5.47 million. During the same quarter in the previous year, the business earned ($1.16) EPS. The company's revenue for the quarter was down 30.2% on a year-over-year basis.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors have recently bought and sold shares of the business. Assetmark Inc. purchased a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth about $34,000. Barclays PLC boosted its stake in Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after buying an additional 2,345 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the 4th quarter valued at $57,000. China Universal Asset Management Co. Ltd. raised its position in Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after purchasing an additional 2,191 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after acquiring an additional 1,782 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the transaction, the chief accounting officer now owns 32,146 shares in the company, valued at $482,190. This trade represents a 7.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of the firm's stock in a transaction on Friday, December 13th. The shares were acquired at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the transaction, the director now directly owns 9,537,643 shares in the company, valued at approximately $131,237,967.68. This trade represents a 11.52 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 27,677 shares of company stock valued at $392,413 over the last 90 days. 8.50% of the stock is currently owned by corporate insiders.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.